Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Jing Christine Ye; Noa Biran; Sandhya Nair; Xiwu Lin; Keqin Qi; Anil Londhe; Eric Ammann; Thomas Renaud; Colleen Kane; Trilok Parekh; Kathleen Gray; Steve Peterson; Luciano J. Costa

doi:10.1016/j.clml.2024.08.003

Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Jing Christine Ye, Noa Biran, Sandhya Nair, Xiwu Lin, Keqin Qi, Anil Londhe, Eric Ammann, Thomas Renaud, Colleen Kane, Trilok Parekh, Kathleen Gray, Steve Peterson, Luciano J. Costa

School of Medicine

Hackensack Meridian School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Talquetamab is approved for treatment of triple-class exposed (TCE) patients with relapsed/refractory multiple myeloma (RRMM). We evaluated the comparative effectiveness of talquetamab in the MonumenTAL-1 study versus real-world physician's choice (RW) treatment. Materials and Methods: An external control arm for MonumenTAL-1 was created from patients in the Flatiron Health database who satisfied MonumenTAL-1 eligibility criteria (n = 629 with 1169 eligible lines of therapy). Patient-level data from MonumenTAL-1 were included for patients who received subcutaneous talquetamab 0.4 mg/kg QW (n = 143) and 0.8 mg/kg Q2W (n = 145). After adjusting for baseline covariate imbalances, comparative effectiveness was assessed for progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS). Results: Baseline covariates were comparable across cohorts after adjustment. Talquetamab 0.4 mg/kg QW and 0.8 mg/kg Q2W cohorts, respectively, showed significant improvement in PFS (HR, 0.55 [95% CI, 0.44-0.69; P < .0001; median, 7.5 vs. 4.0 months] and 0.40 [95% CI, 0.31-0.53; P < .0001; median, 14.2 vs. 4.0 months]), TTNT (HR, 0.59 [95% CI, 0.47-0.74; P < .0001; median, 9.1 vs. 5.1 months] and 0.45 [95% CI, 0.35-0.59; P < .0001; median, 13.3 vs. 5.1 months]), and OS (HR, 0.56 [95% CI, 0.40-0.78; P = .0007; median, NR vs. 16.5 months] and 0.48 [95% CI, 0.33-0.70; P = 0.0002; median NR vs. 15.9 months]) versus RW treatment. Conclusion: Both talquetamab schedules demonstrated superior effectiveness over RW treatment for all outcomes assessed. These data suggest talquetamab as an effective immunotherapy option in patients with TCE RRMM.

Original language	English
Pages (from-to)	124-134.e5
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	25
Issue number	2
DOIs	https://doi.org/10.1016/j.clml.2024.08.003
State	Published - Feb 2025

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Keywords

Bispecific antibody
Flatiron health
G protein–coupled receptor class C group 5 member D (GPRC5D)
Indirect treatment comparison
MonumenTAL-1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2024.08.003

Cite this

Ye, J. C., Biran, N., Nair, S., Lin, X., Qi, K., Londhe, A., Ammann, E., Renaud, T., Kane, C., Parekh, T., Gray, K., Peterson, S., & Costa, L. J. (2025). Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 25(2), 124-134.e5. https://doi.org/10.1016/j.clml.2024.08.003

@article{df4eb14ba26a46449ad87d6e4d90edc8,

title = "Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma",

abstract = "Background: Talquetamab is approved for treatment of triple-class exposed (TCE) patients with relapsed/refractory multiple myeloma (RRMM). We evaluated the comparative effectiveness of talquetamab in the MonumenTAL-1 study versus real-world physician's choice (RW) treatment. Materials and Methods: An external control arm for MonumenTAL-1 was created from patients in the Flatiron Health database who satisfied MonumenTAL-1 eligibility criteria (n = 629 with 1169 eligible lines of therapy). Patient-level data from MonumenTAL-1 were included for patients who received subcutaneous talquetamab 0.4 mg/kg QW (n = 143) and 0.8 mg/kg Q2W (n = 145). After adjusting for baseline covariate imbalances, comparative effectiveness was assessed for progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS). Results: Baseline covariates were comparable across cohorts after adjustment. Talquetamab 0.4 mg/kg QW and 0.8 mg/kg Q2W cohorts, respectively, showed significant improvement in PFS (HR, 0.55 [95% CI, 0.44-0.69; P < .0001; median, 7.5 vs. 4.0 months] and 0.40 [95% CI, 0.31-0.53; P < .0001; median, 14.2 vs. 4.0 months]), TTNT (HR, 0.59 [95% CI, 0.47-0.74; P < .0001; median, 9.1 vs. 5.1 months] and 0.45 [95% CI, 0.35-0.59; P < .0001; median, 13.3 vs. 5.1 months]), and OS (HR, 0.56 [95% CI, 0.40-0.78; P = .0007; median, NR vs. 16.5 months] and 0.48 [95% CI, 0.33-0.70; P = 0.0002; median NR vs. 15.9 months]) versus RW treatment. Conclusion: Both talquetamab schedules demonstrated superior effectiveness over RW treatment for all outcomes assessed. These data suggest talquetamab as an effective immunotherapy option in patients with TCE RRMM.",

keywords = "Bispecific antibody, Flatiron health, G protein–coupled receptor class C group 5 member D (GPRC5D), Indirect treatment comparison, MonumenTAL-1",

author = "Ye, {Jing Christine} and Noa Biran and Sandhya Nair and Xiwu Lin and Keqin Qi and Anil Londhe and Eric Ammann and Thomas Renaud and Colleen Kane and Trilok Parekh and Kathleen Gray and Steve Peterson and Costa, {Luciano J.}",

note = "Publisher Copyright: {\textcopyright} 2024",

year = "2025",

month = feb,

doi = "10.1016/j.clml.2024.08.003",

language = "English",

volume = "25",

pages = "124--134.e5",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "2",

}

Ye, JC, Biran, N, Nair, S, Lin, X, Qi, K, Londhe, A, Ammann, E, Renaud, T, Kane, C, Parekh, T, Gray, K, Peterson, S & Costa, LJ 2025, 'Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma', Clinical Lymphoma, Myeloma and Leukemia, vol. 25, no. 2, pp. 124-134.e5. https://doi.org/10.1016/j.clml.2024.08.003

TY - JOUR

T1 - Talquetamab Versus Real-World Physician's Choice Treatment

T2 - Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

AU - Ye, Jing Christine

AU - Biran, Noa

AU - Nair, Sandhya

AU - Lin, Xiwu

AU - Qi, Keqin

AU - Londhe, Anil

AU - Ammann, Eric

AU - Renaud, Thomas

AU - Kane, Colleen

AU - Parekh, Trilok

AU - Gray, Kathleen

AU - Peterson, Steve

AU - Costa, Luciano J.

PY - 2025/2

Y1 - 2025/2

N2 - Background: Talquetamab is approved for treatment of triple-class exposed (TCE) patients with relapsed/refractory multiple myeloma (RRMM). We evaluated the comparative effectiveness of talquetamab in the MonumenTAL-1 study versus real-world physician's choice (RW) treatment. Materials and Methods: An external control arm for MonumenTAL-1 was created from patients in the Flatiron Health database who satisfied MonumenTAL-1 eligibility criteria (n = 629 with 1169 eligible lines of therapy). Patient-level data from MonumenTAL-1 were included for patients who received subcutaneous talquetamab 0.4 mg/kg QW (n = 143) and 0.8 mg/kg Q2W (n = 145). After adjusting for baseline covariate imbalances, comparative effectiveness was assessed for progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS). Results: Baseline covariates were comparable across cohorts after adjustment. Talquetamab 0.4 mg/kg QW and 0.8 mg/kg Q2W cohorts, respectively, showed significant improvement in PFS (HR, 0.55 [95% CI, 0.44-0.69; P < .0001; median, 7.5 vs. 4.0 months] and 0.40 [95% CI, 0.31-0.53; P < .0001; median, 14.2 vs. 4.0 months]), TTNT (HR, 0.59 [95% CI, 0.47-0.74; P < .0001; median, 9.1 vs. 5.1 months] and 0.45 [95% CI, 0.35-0.59; P < .0001; median, 13.3 vs. 5.1 months]), and OS (HR, 0.56 [95% CI, 0.40-0.78; P = .0007; median, NR vs. 16.5 months] and 0.48 [95% CI, 0.33-0.70; P = 0.0002; median NR vs. 15.9 months]) versus RW treatment. Conclusion: Both talquetamab schedules demonstrated superior effectiveness over RW treatment for all outcomes assessed. These data suggest talquetamab as an effective immunotherapy option in patients with TCE RRMM.

AB - Background: Talquetamab is approved for treatment of triple-class exposed (TCE) patients with relapsed/refractory multiple myeloma (RRMM). We evaluated the comparative effectiveness of talquetamab in the MonumenTAL-1 study versus real-world physician's choice (RW) treatment. Materials and Methods: An external control arm for MonumenTAL-1 was created from patients in the Flatiron Health database who satisfied MonumenTAL-1 eligibility criteria (n = 629 with 1169 eligible lines of therapy). Patient-level data from MonumenTAL-1 were included for patients who received subcutaneous talquetamab 0.4 mg/kg QW (n = 143) and 0.8 mg/kg Q2W (n = 145). After adjusting for baseline covariate imbalances, comparative effectiveness was assessed for progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS). Results: Baseline covariates were comparable across cohorts after adjustment. Talquetamab 0.4 mg/kg QW and 0.8 mg/kg Q2W cohorts, respectively, showed significant improvement in PFS (HR, 0.55 [95% CI, 0.44-0.69; P < .0001; median, 7.5 vs. 4.0 months] and 0.40 [95% CI, 0.31-0.53; P < .0001; median, 14.2 vs. 4.0 months]), TTNT (HR, 0.59 [95% CI, 0.47-0.74; P < .0001; median, 9.1 vs. 5.1 months] and 0.45 [95% CI, 0.35-0.59; P < .0001; median, 13.3 vs. 5.1 months]), and OS (HR, 0.56 [95% CI, 0.40-0.78; P = .0007; median, NR vs. 16.5 months] and 0.48 [95% CI, 0.33-0.70; P = 0.0002; median NR vs. 15.9 months]) versus RW treatment. Conclusion: Both talquetamab schedules demonstrated superior effectiveness over RW treatment for all outcomes assessed. These data suggest talquetamab as an effective immunotherapy option in patients with TCE RRMM.

KW - Bispecific antibody

KW - Flatiron health

KW - G protein–coupled receptor class C group 5 member D (GPRC5D)

KW - Indirect treatment comparison

KW - MonumenTAL-1

UR - http://www.scopus.com/inward/record.url?scp=85203815068&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2024.08.003

DO - 10.1016/j.clml.2024.08.003

M3 - Article

C2 - 39271448

SN - 2152-2650

VL - 25

SP - 124-134.e5

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 2

ER -

Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Abstract

ASJC Scopus subject areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this